All News

The World Health Organization’s (WHO) Fracture Risk Assessment tool (FRAX) severely underestimates risk of fragility fracture (FF) in certain patients, according to a new study. Published in the Journal of Clinical Endocrinology & Metabolism, the findings are by Canadian investigators.

Real-feel devices and virtual reality headsets, both in the works and on the market, have applications for physicians and their patients.

“The c-section you do today impacts the future health of the woman you’re caring for.” So said Aaron B. Caughey, MD, of Oregon Health & Science University, Portland, in his lunch-and-learn “The Cesarean Epidemic: Etiologies, Outcomes and Potential Solutions” on Monday. What’s more, he pointed out, “the c-section you do today leads to the repeat … [which] leads to the repeat … [which] leads to the accreta in 8 years.” But Caughey did not place blame for the so-called epidemic with either doctors or patients.

A small study presented at the 2014 ACOG Annual Clinical Meeting suggests that a selective estrogen receptor modulator (SERM) plus estrogen may have promise in treatment of perimenopausal symptoms. According to Japanese researchers, the combination-known as tissue-selective estrogen complex-improved climacteric symptoms and bone resorption markers without severe side effects.

Concerns about asymptomatic sexually transmitted infection (STI) in women at high risk should not delay placement of an intrauterine device (IUD) in women who also are at risk of undesired pregnancy, according to a study by investigators from the University of Pittsburgh. The results, in 366 patients from an inner-city clinic, were presented at the 2014 ACOG Annual Clinical Meeting.

A systematic review of Smartphone reminder applications (apps) by investigators at the Ohio State University shows that they may be useful as back-up reminders for patients on oral contraceptives (OCs). The research was presented at the 2014 ACOG Annual Clinical Meeting.

Contemporary OB/GYN editorial board member Ilana Cass, MD, offers perspective on the recent FDA approval of the first-ever alternative to Pap smear cytology cervical screening.